Literature DB >> 22724320

[Update on current care guidelines: benign prostatic hyperplasia].

Teuvo Tammela, Martti Nurmi, Anssi Pétas, Raija Sipilä, Kimmo Taari.   

Abstract

Most benign prostatic hyperplasia (BPH) patients can be diagnosed and treated in primary care. Evaluation requires a medical history and a symptom score (DAN-PSS or IPSS) and a careful physical examination including a digital rectal examination. Careful follow-up and medical therapy are the usual first-line management options in uncomplicated BPH. Combination therapy with both alpha-blocker and 5alpha-reductase inhibitor is the most effective medical treatment modality. Transurethral resection (TURP) is a safe and effective way of treating BPH. The green laser is the most promising new endoscopic treatment modality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22724320

Source DB:  PubMed          Journal:  Duodecim        ISSN: 0012-7183


  2 in total

1.  Combined low-frequency ultrasound and microbubble contrast agent for the treatment of benign prostatic hyperplasia.

Authors:  Shao-ling Yang; Ke-qiang Tang; Wen-kun Bai; Yi-Wen Zhao; E Shen; Jun-jia Tao; Bing Hu
Journal:  J Endourol       Date:  2013-08       Impact factor: 2.942

2.  α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines.

Authors:  Xiao-Feng Xu; Guo-Xiong Liu; Cong Zhu; Xi-Min Qiao; Shao-Fu Yu; Tong Deng; Ying-Hui Jin
Journal:  Front Pharmacol       Date:  2020-03-25       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.